Risks of Comorbidities in Patients With Palmoplantar Pustulosis vs Patients With Psoriasis Vulgaris or Pompholyx in Korea.

Importance: Palmoplantar pustulosis (PPP) has been reported to be accompanied by systemic conditions. However, the risks of comorbidities in patients with PPP have rarely been evaluated. Objective: To assess the risks of comorbidities in patients with PPP compared with patients with psoriasis vulgaris or pompholyx. Design, Setting, and Participants: This nationwide population-based cross-sectional study used data from the Korean National Health Insurance database and the National Health Screening Program collected from January 1, 2010, to December 31, 2019. Data were analyzed from July 1, 2020, to October 31, 2021. Korean patients diagnosed with PPP, psoriasis vulgaris, or pompholyx who visited a dermatologist between January 1, 2010, and December 31, 2019, were enrolled. Exposures: Presence of PPP. Main Outcomes and Measures: The risks of comorbidities among patients with PPP vs patients with psoriasis vulgaris or pompholyx were evaluated using a multivariable logistic regression model. Results: A total of 37 399 patients with PPP (mean [SD] age, 48.98 [17.20] years; 51.7% female), 332 279 patients with psoriasis vulgaris (mean [SD] age, 47.29 [18.34] years; 58.7% male), and 365 415 patients with pompholyx (mean [SD] age, 40.92 [17.63] years; 57.4% female) were included in the analyses. Compared with patients with pompholyx, those with PPP had significantly higher risks of developing psoriasis vulgaris (adjusted odds ratio [aOR], 72.96; 95% CI, 68.19-78.05; P < .001), psoriatic arthritis (aOR, 8.06; 95% CI, 6.55-9.92; P < .001), ankylosing spondylitis (aOR, 1.91; 95% CI, 1.61-2.27; P < .001), type 1 diabetes (aOR, 1.33; 95% CI, 1.16-1.52; P < .001), type 2 diabetes (aOR, 1.33; 95% CI, 1.29-1.38; P < .001), Graves disease (aOR, 1.25; 95% CI, 1.11-1.42; P < .001), Crohn disease (aOR, 1.63; 95% CI, 1.11-2.40; P = .01), and vitiligo (aOR, 1.87; 95% CI, 1.65-2.12; P < .001) after adjusting for demographic covariates. The risks of ankylosing spondylitis (aOR, 1.37; 95% CI, 1.16-1.62; P < .001) and Graves disease (aOR, 1.40; 95% CI, 1.23-1.58; P < .001) were significantly higher among patients with PPP vs psoriasis vulgaris. However, the risks of psoriatic arthritis (aOR, 0.54; 95% CI, 0.47-0.63; P < .001), systemic lupus erythematosus (aOR, 0.67; 95% CI, 0.46-0.97; P = .04), Sjögren syndrome (aOR, 0.70; 95% CI, 0.50-0.96; P = .03), systemic sclerosis (aOR, 0.29; 95% CI, 0.11-0.77; P = .01), vitiligo (aOR, 0.53; 95% CI, 0.47-0.60; P < .001), and alopecia areata (aOR, 0.88; 95% CI, 0.81-0.95; P = .001) were significantly lower among those with PPP vs psoriasis vulgaris. Conclusions and Relevance: The results of this cross-sectional study suggest that patients with PPP have an overlapping comorbidity profile with patients with psoriasis vulgaris but not patients with pompholyx. However, the risks of comorbidities among patients with PPP may be substantially different from those among patients with psoriasis vulgaris.

Hidradenitis palmoplantar idiopática: ¿es siempre necesaria la biopsia? / Idiopathic palmoplantar hidradenitis: is biopsy always necessary?

La hidradenitis palmoplantar idiopática (HPPI) es una dermatosis neutrofílica que cursa con placas eritematoso-edematosas en las plantas de los pies y, en ocasiones, en las palmas de las manos. Estas lesiones se presentan en niños sin antecedentes de medicación ni manifestaciones sistémicas. Se postula que determinados factores mecánicos afectarían a las glándulas ecrinas inmaduras. El tratamiento es controvertido, aunque se ha observado que se puede manejar de forma conservadora. Por otro lado, el diagnóstico histológico, que presenta hallazgos típicos, no sería necesario realizarlo en todos los casos, puesto que la mayoría presenta una clínica característica con resolución espontánea en menos de 3 semanas. Presentamos dos casos de HPPI en niños (AU)

Idiopathic palmoplantar hidradenitis (IPPH) is a neutrophilic dermatosis that causes erythematous plaques in plants and sometimes in palms. These injuries occur in children with no history of medication or systemic manifestations. It is postulated that mechanical factors affect immature eccrine glands. The treatment is controversial, although we know that it can be conservatively managed. On the other hand, histological diagnosis, which presents typical findings, would not be necessary in all cases, since most of them present characteristic symptoms and spontaneous remission in less than three weeks. We present two cases of IPPH in children (AU)

Dyshidrotic Eczema and Its Relationship to Metal Allergy.

Dyshidrotic eczema, also known as dyshidrotic dermatitis or pompholyx, is characterized by pruritic, small tense vesicles mainly on the palmoplantar region and lateral and ventral surfaces of the fingers. While its etiology appears to be related to sweating, as dyshidrotic eczema often occurs in an individual with hyperhidrosis, and the spring allergy season, histologic examination shows an eczematous reaction around the sweat ducts which is not associated with abnormalities of the sweat ducts. More recently, the nomenclature of 'acute and recurrent vesicular hand dermatitis' has been proposed to reflect clinical features of dyshidrotic eczema. Although the exact etiology of dyshidrotic eczema remains unknown, given the presence of metal allergy in patients with dyshidrotic eczema and the improvement of the symptoms by removing metal allergen, metal allergy is regarded as one of the important potential etiologic factors for dyshidrotic eczema.

Remarkable improvement of relapsing dyshidrotic eczema after treatment of coexistant hyperhidrosis with oxybutynin.

Dyshidrotic hand eczema is a common condition, which can be resistant to various treatments. Although a number of etiologic factors are involved in the pathogenesis of dyshidrotic eczema, hyperhidrosis is assumed to play a significant role. Oxybutynin is an alternative treatment for hyperhidrosis. We present the cases of two patients suffering from hyperhidrosis and dyshidrotic eczema, who were treated with oxybutynin with impressive results.

Larva migrans cutánea en un paciente viajero portador de dishidrosis: a propósito de un caso clínico / Cutaneous larva migrans in a traveling patient with dyshidrosis: a case report

Larva migrans cutánea es el resultado de una infección por nematodos y muestra una erupción serpiginosa característica. Con el aumento de los viajes a zonas tropicales, muchos pacientes pueden volver con ésta infección, que es a menudo, mal diagnosticada o tratada incorrectamente. Esta enfermedad cutánea parasitaria es causada por la migración de larvas provenientes de animales en la epidermis humana.

Cutaneous larva migrans is a result of a nematode infection and shows a characteristic creeping eruption. As travel to the tropics zone increases, many patients may be returning with this infection, which is often misdiagnosed or treated incorrectly. This parasitic skin disease is caused by the migration of animal hookworm larvae in the human epidermis.

Hiperhidrosis localizada por fluoxetina / Localized hyperhidrosis due to fluoxetine

La fluoxetina es uno de los fármacos antidepresivos más utilizados actualmente. Entre sus efectos secundarios está la hiperhidrosis. Presentamos los casos de dos pacientes en tratamiento con fluoxetina por parte del Servicio de Psiquiatría de nuestro hospital que acudieron al Servicio de Dermatología por presentar ambos un cuadro de intensa hiperhidrosis localizada, el primero a nivel del cuero cabelludo y el segundo en axilas, palmas y plantas. En ambos casos los síntomas cedieron tras retirar el fármaco. (AU)

Resolution of dyshidrotic dermatitis of the hand after treatment with continuous positive airway pressure for obstructive sleep apnea.

Eczema of the palm and obstructive sleep apnea (OSA) are common disorders. Proinflammatory cytokines and cell adhesion molecules are elevated in both of these disorders. We describe an unusual patient with OSA who had recurrent free remission of dermatitis after treatment with continuous positive airway pressure. We speculate that the resolution of the patient's skin condition may reflect the effects of increased tissue oxygenation during sleep, reduced sleep fragmentation, and/or a reduction in sympathetic tone associated with successful sleep apnea treatment.

[Dyshidrosis and acral purpura during polymorphic dermatitis in pregnancy: 2 cases]. / Dyshidrose et purpura acral au cours de la dermatite polymorphe gravidique: 2 cas.

BACKGROUND: We describe two severe cases of polymorphic eruption of pregnancy associated with dyshidrosis and purpuric lesions. CASE-REPORT: Two patients, primigravida at 35 and 34 weeks of amenorrhea, were admitted in our department for a severe and itchy eruption. In the first case, some papular lesions were particularly concentrated on the abdominal striae, associated with vesicles on the limbs. There were plantar dyshidrosis and purpuric macules on the toes. In the second case, there were a maculopapular eruption on the abdomen and limbs, some vesicles and bullae of palms and soles, and a purpura of heels. In both cases, the skin biopsy showed dermic inflammatory, direct immunofluorescence and Pemphigoide Gestationis Factor research were negatives. The two patients were treated with betamethasone dipropionate (Diprosone(R)), and hydroxyzine (Atarax(R)). They gave birth to healthy babies. DISCUSSION: Dyshidrosis is not exceptional in polymorphic eruption of pregnancy. Indeed, in the several series of polymorphic eruption of pregnancy we checked, a pompholyx distribution was observed in 5 p. 100 of the cases. It is not necessary a sign of pemphigoid gestationis, even if this localization is commonly observed. The purpuric lesions are unusual because, according to our knowledge, there is no description of purpura associated with palmoplantar lesions in polymorphic eruption of pregnancy. The purpuric lesions may be secondary to high capillary permeability, increased by severe dermic inflammation of the polymorphic eruption of pregnancy and, possibly, high level of circulating estrogens.